Taiho’s Lonsurf (trifluridine/tipiracil) + Bevacizumab Receives EC’s Approval as 3L Treatment of Refractory Metastatic Colorectal Cancer
Shots:
- The EC has approved Lonsurf + bevacizumab for adult patients with mCRC who received 2 prior anti-cancer treatments incl. fluoropyrimidine-, oxaliplatin & irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. The trial was conducted by Servier & Taiho Oncology
- The approval was based on the P-III trial (SUNLIGHT) evaluating trifluridine/tipiracil + bevacizumab vs trifluridine/tipiracil alone in a ratio (1:1) in 492 patients. The primary objective was to evaluate trifluridine/tipiracil + bevacizumab in terms of OS & 2EPs were PFS, ORR, DCR & QoL, safety & tolerability
- The marketing authorization is valid in 27 EU countries, Iceland, Northern Ireland, Liechtenstein & Norway. Lonsurf, an oral nucleoside antitumor agent discovered & developed by Taiho Pharmaceutical
Ref: Taiho | Image: Taiho
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
